In this video from OncLive, Dr. Peter Martin discusses potential changes in the future treatment of younger patients with mantle cell lymphoma (MCL), as well as new lines of therapy currently being developed for all patients with MCL. These new therapies include Bruton’s tyrosine kinase inhibitors, PI3 kinase inhibitors, Bcl-2 inhibitors, immunomodulatory drugs, and immunotherapy agents.
In the Lymphoma Program our patient care is informed by our clinical research. A full listing of available trials for MCL can be found on our clinical trials website.
